Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

Nicholas P. Restifo, Francesco M. Marincola, Yutaka Kawakami, Jeff Taubenberger, John R. Yannelli, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Background: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the α chain and a non-covalently associated, soluble protein called beta2- microglobulin (β2m). Loss of β2m generally eliminates antigen recognition by antitumor CD8+ T cells. Purpose: We studied the loss of β2m as a potential means of tumor escape from immune recognition in a cohort of patients receiving immunotherapy. Methods: We successfully grew 13 independent tumor cell cultures from tumor specimens obtained from 13 patients in a cohort of 411 consecutive patients undergoing immunotherapy for metastatic melanoma and for whom tumor specimens were available. These cell lines, as well as another melanoma cell line (called 1074mel) that had been derived from tumor obtained from a patient in a cytokine-gene therapy study, were characterized in vitro cytofluorometrically for MHC class I expression and by northern and western blot analyses for messenger RNA (mRNA) and protein expression, respectively, and ex vivo by immunohistochemistry. Results: After one melanoma cell line (107mel) was found not to express functional β2m by cytofluorometric analysis, four (31%) of the 13 newly established melanoma cell lines were found to have an absolute lack of functional MHC class I expression. Northern blot analysis of RNA extracted from the five cell lines exhibiting no functional MHC class I expression showed that these cells contained normal levels of α-chain mRNA but variable levels of β2m mRNA. In addition, no immunoreactive β2m protein was detected by western blot analysis. When human β2m was transiently expressed with the use of a recombinant vaccinia virus, cell-surface MHC class I expression was reconstituted and the ability of these five cell lines to present endogenous antigens was restored. Immunohistochemical staining of tumor sections revealed a lack of immunoreactive MHC class I in vivo, supporting the notion that the in vitro observations were not artifactual. Furthermore, archival tumor sections obtained from patients prior to immunotherapy were available from three patients and were found to be β2m positive. This result was consistent with the hypothesis that loss of β2m resulted from immunotherapy. Conclusions: These data suggest that the loss of β2m may be a mechanism whereby tumor cells can acquire immunoresistance. This study represents the first characterization of a molecular route of escape of tumors from immune recognition in a cohort of patients being treated with immunotherapy.

Original languageEnglish (US)
Pages (from-to)100-108
Number of pages9
JournalJournal of the National Cancer Institute
Volume88
Issue number2
DOIs
StatePublished - Jan 17 1996
Externally publishedYes

Fingerprint

Immunotherapy
Melanoma
Major Histocompatibility Complex
Cell Line
Neoplasms
Tumor Escape
T-Lymphocytes
Antigens
Northern Blotting
Messenger RNA
Western Blotting
Proteins
Vaccinia virus
Membrane Glycoproteins
Genetic Therapy
Cell Culture Techniques
Immunohistochemistry
RNA
Staining and Labeling
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Restifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996). Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. Journal of the National Cancer Institute, 88(2), 100-108. https://doi.org/10.1093/jnci/88.2.100

Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. / Restifo, Nicholas P.; Marincola, Francesco M.; Kawakami, Yutaka; Taubenberger, Jeff; Yannelli, John R.; Rosenberg, Steven A.

In: Journal of the National Cancer Institute, Vol. 88, No. 2, 17.01.1996, p. 100-108.

Research output: Contribution to journalArticle

Restifo, NP, Marincola, FM, Kawakami, Y, Taubenberger, J, Yannelli, JR & Rosenberg, SA 1996, 'Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy', Journal of the National Cancer Institute, vol. 88, no. 2, pp. 100-108. https://doi.org/10.1093/jnci/88.2.100
Restifo, Nicholas P. ; Marincola, Francesco M. ; Kawakami, Yutaka ; Taubenberger, Jeff ; Yannelli, John R. ; Rosenberg, Steven A. / Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. In: Journal of the National Cancer Institute. 1996 ; Vol. 88, No. 2. pp. 100-108.
@article{b0d81a0183ac46cc86a956237d1bef6e,
title = "Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy",
abstract = "Background: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the α chain and a non-covalently associated, soluble protein called beta2- microglobulin (β2m). Loss of β2m generally eliminates antigen recognition by antitumor CD8+ T cells. Purpose: We studied the loss of β2m as a potential means of tumor escape from immune recognition in a cohort of patients receiving immunotherapy. Methods: We successfully grew 13 independent tumor cell cultures from tumor specimens obtained from 13 patients in a cohort of 411 consecutive patients undergoing immunotherapy for metastatic melanoma and for whom tumor specimens were available. These cell lines, as well as another melanoma cell line (called 1074mel) that had been derived from tumor obtained from a patient in a cytokine-gene therapy study, were characterized in vitro cytofluorometrically for MHC class I expression and by northern and western blot analyses for messenger RNA (mRNA) and protein expression, respectively, and ex vivo by immunohistochemistry. Results: After one melanoma cell line (107mel) was found not to express functional β2m by cytofluorometric analysis, four (31{\%}) of the 13 newly established melanoma cell lines were found to have an absolute lack of functional MHC class I expression. Northern blot analysis of RNA extracted from the five cell lines exhibiting no functional MHC class I expression showed that these cells contained normal levels of α-chain mRNA but variable levels of β2m mRNA. In addition, no immunoreactive β2m protein was detected by western blot analysis. When human β2m was transiently expressed with the use of a recombinant vaccinia virus, cell-surface MHC class I expression was reconstituted and the ability of these five cell lines to present endogenous antigens was restored. Immunohistochemical staining of tumor sections revealed a lack of immunoreactive MHC class I in vivo, supporting the notion that the in vitro observations were not artifactual. Furthermore, archival tumor sections obtained from patients prior to immunotherapy were available from three patients and were found to be β2m positive. This result was consistent with the hypothesis that loss of β2m resulted from immunotherapy. Conclusions: These data suggest that the loss of β2m may be a mechanism whereby tumor cells can acquire immunoresistance. This study represents the first characterization of a molecular route of escape of tumors from immune recognition in a cohort of patients being treated with immunotherapy.",
author = "Restifo, {Nicholas P.} and Marincola, {Francesco M.} and Yutaka Kawakami and Jeff Taubenberger and Yannelli, {John R.} and Rosenberg, {Steven A.}",
year = "1996",
month = "1",
day = "17",
doi = "10.1093/jnci/88.2.100",
language = "English (US)",
volume = "88",
pages = "100--108",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

AU - Restifo, Nicholas P.

AU - Marincola, Francesco M.

AU - Kawakami, Yutaka

AU - Taubenberger, Jeff

AU - Yannelli, John R.

AU - Rosenberg, Steven A.

PY - 1996/1/17

Y1 - 1996/1/17

N2 - Background: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the α chain and a non-covalently associated, soluble protein called beta2- microglobulin (β2m). Loss of β2m generally eliminates antigen recognition by antitumor CD8+ T cells. Purpose: We studied the loss of β2m as a potential means of tumor escape from immune recognition in a cohort of patients receiving immunotherapy. Methods: We successfully grew 13 independent tumor cell cultures from tumor specimens obtained from 13 patients in a cohort of 411 consecutive patients undergoing immunotherapy for metastatic melanoma and for whom tumor specimens were available. These cell lines, as well as another melanoma cell line (called 1074mel) that had been derived from tumor obtained from a patient in a cytokine-gene therapy study, were characterized in vitro cytofluorometrically for MHC class I expression and by northern and western blot analyses for messenger RNA (mRNA) and protein expression, respectively, and ex vivo by immunohistochemistry. Results: After one melanoma cell line (107mel) was found not to express functional β2m by cytofluorometric analysis, four (31%) of the 13 newly established melanoma cell lines were found to have an absolute lack of functional MHC class I expression. Northern blot analysis of RNA extracted from the five cell lines exhibiting no functional MHC class I expression showed that these cells contained normal levels of α-chain mRNA but variable levels of β2m mRNA. In addition, no immunoreactive β2m protein was detected by western blot analysis. When human β2m was transiently expressed with the use of a recombinant vaccinia virus, cell-surface MHC class I expression was reconstituted and the ability of these five cell lines to present endogenous antigens was restored. Immunohistochemical staining of tumor sections revealed a lack of immunoreactive MHC class I in vivo, supporting the notion that the in vitro observations were not artifactual. Furthermore, archival tumor sections obtained from patients prior to immunotherapy were available from three patients and were found to be β2m positive. This result was consistent with the hypothesis that loss of β2m resulted from immunotherapy. Conclusions: These data suggest that the loss of β2m may be a mechanism whereby tumor cells can acquire immunoresistance. This study represents the first characterization of a molecular route of escape of tumors from immune recognition in a cohort of patients being treated with immunotherapy.

AB - Background: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the α chain and a non-covalently associated, soluble protein called beta2- microglobulin (β2m). Loss of β2m generally eliminates antigen recognition by antitumor CD8+ T cells. Purpose: We studied the loss of β2m as a potential means of tumor escape from immune recognition in a cohort of patients receiving immunotherapy. Methods: We successfully grew 13 independent tumor cell cultures from tumor specimens obtained from 13 patients in a cohort of 411 consecutive patients undergoing immunotherapy for metastatic melanoma and for whom tumor specimens were available. These cell lines, as well as another melanoma cell line (called 1074mel) that had been derived from tumor obtained from a patient in a cytokine-gene therapy study, were characterized in vitro cytofluorometrically for MHC class I expression and by northern and western blot analyses for messenger RNA (mRNA) and protein expression, respectively, and ex vivo by immunohistochemistry. Results: After one melanoma cell line (107mel) was found not to express functional β2m by cytofluorometric analysis, four (31%) of the 13 newly established melanoma cell lines were found to have an absolute lack of functional MHC class I expression. Northern blot analysis of RNA extracted from the five cell lines exhibiting no functional MHC class I expression showed that these cells contained normal levels of α-chain mRNA but variable levels of β2m mRNA. In addition, no immunoreactive β2m protein was detected by western blot analysis. When human β2m was transiently expressed with the use of a recombinant vaccinia virus, cell-surface MHC class I expression was reconstituted and the ability of these five cell lines to present endogenous antigens was restored. Immunohistochemical staining of tumor sections revealed a lack of immunoreactive MHC class I in vivo, supporting the notion that the in vitro observations were not artifactual. Furthermore, archival tumor sections obtained from patients prior to immunotherapy were available from three patients and were found to be β2m positive. This result was consistent with the hypothesis that loss of β2m resulted from immunotherapy. Conclusions: These data suggest that the loss of β2m may be a mechanism whereby tumor cells can acquire immunoresistance. This study represents the first characterization of a molecular route of escape of tumors from immune recognition in a cohort of patients being treated with immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029670776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029670776&partnerID=8YFLogxK

U2 - 10.1093/jnci/88.2.100

DO - 10.1093/jnci/88.2.100

M3 - Article

VL - 88

SP - 100

EP - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 2

ER -